$EW insider trading
Over the last 12 months, Edwards Lifesciences insiders reported no purchases and 37 sales totaling $23.2M across SEC Form 4 filings. 57% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $23.2M 37 events
- Events · 12m
- 37 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 57% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Lippis Daniel J.CVP, TAVR · O | ▼ Sale | 619 | $87.51 | $54K | -1.5% | plan |
| Aug 31, 2026 | Dahl Andrew M.SVP, Corporate Controller · O | ▼ Sale | 544 | $91.06 | $50K | -3.5% | — |
| Aug 28, 2026 | Bruls AnnetteCVP, EMEACLA · O | ▼ Sale | 2,644 | $89.98 | $238K | -12.8% | — |
| Aug 26, 2026 | Chopra DaveenCVP, TMTT, Surgical & IHFM · O | ▼ Sale | 31,800 | $91.02 | $2.9M | -41.8% | 2 tranches |
| Aug 26, 2026 | Markowitz WayneCVP, JAPAC · O | ▼ Sale | 1,240 | $91.46 | $113K | -5.8% | — |
| Aug 11, 2026 | Lippis Daniel J.CVP, TAVR · O | ▼ Sale | 619 | $92.03 | $57K | -1.5% | plan |
| Jul 30, 2026 | Markowitz WayneCVP, JAPAC · O | ▼ Sale | 146.313 | $86.03 | $13K | -0.7% | — |
| Jul 28, 2026 | Markowitz WayneCVP, JAPAC · O | ▼ Sale | 9,628 | $85.06 | $819K | -30.8% | — |
| Jul 27, 2026 | Zovighian Bernard JCEO · O·D | ▼ Sale | 2,920.551 | $83.93 | $245K | -24.7% | indirect |
| Jul 10, 2026 | Lippis Daniel J.CVP, TAVR · O | ▼ Sale | 619 | $91.7 | $57K | -1.5% | plan |
| Jun 30, 2026 | Lippis Daniel J.CVP, TAVR · O | ▼ Sale | 619 | $91.4 | $57K | -1.5% | plan |
| Jun 17, 2026 | Zovighian Bernard JCEO · O·D | ▼ Sale | 523 | $87.92 | $46K | -4.3% | plan · indirect |
| May 29, 2026 | Dahl Andrew M.SVP, Corporate Controller · O | ▼ Sale | 567.527 | $86.08 | $49K | -3.6% | — |
| May 27, 2026 | BOBO DONALD E JRCVP,Strategy/Corp Development · O | ▼ Sale | 23,145 | $86.42 | $2.0M | -19% | indirect |
| May 11, 2026 | Markowitz WayneCVP, JAPAC · O | ▼ Sale | 593 | $79.73 | $47K | -2.7% | — |
| May 4, 2026 | Lippis Daniel J.CVP, TAVR · O | ▼ Sale | 2,038 | $83.49 | $170K | -5.7% | plan · 3 tranches |
| Apr 9, 2026 | Ullem Scott B.CVP, Chief Financial Officer · O | ▼ Sale | 13,000 | $80.04 | $1.0M | -24.7% | plan · 2 tranches |
| Apr 6, 2026 | Lippis Daniel J.CVP, TAVR · O | ▼ Sale | 1,019 | $80.98 | $83K | -2.9% | plan |
| Apr 2, 2026 | BOBO DONALD E JRCVP,Strategy/Corp Development · O | ▼ Sale | 22,680 | $80.16 | $1.8M | -51.6% | plan · 2 tranches |
| Mar 11, 2026 | Ullem Scott B.CVP, Chief Financial Officer · O | ▼ Sale | 13,000 | $84.92 | $1.1M | -24.7% | plan · 2 tranches |
| Mar 11, 2026 | Lippis Daniel J.CVP, TAVR · O | ▼ Sale | 1,019 | $85.38 | $87K | -2.9% | plan |
| Mar 2, 2026 | BOBO DONALD E JRCVP,Strategy/Corp Development · O | ▼ Sale | 11,340 | $85.93 | $974K | -34.8% | plan |
| Feb 25, 2026 | BOBO DONALD E JRCVP,Strategy/Corp Development · O | ▼ Sale | 24,000 | $83.84 | $2.0M | -53% | — |
| Feb 12, 2026 | Zovighian Bernard JCEO · O·D | ▼ Sale | 22,430 | $76.67 | $1.7M | -21.1% | 2 tranches |
| Jan 9, 2026 | Lippis Daniel J.CVP, TAVR · O | ▼ Sale | 1,019 | $85.7 | $87K | -4.4% | plan |
| Jan 6, 2026 | BOBO DONALD E JRCVP,Strategy/Corp Development · O | ▼ Sale | 11,340 | $85.66 | $971K | -26.2% | plan · 2 tranches |
| Dec 12, 2025 | BOBO DONALD E JRCVP,Strategy/Corp Development · O | ▼ Sale | 11,386.118 | $83.76 | $954K | -22.6% | 2 tranches |
| Dec 12, 2025 | Lippis Daniel J.CVP, JAPAC · O | ▼ Sale | 1,019 | $84.03 | $86K | -4.4% | plan |
| Dec 12, 2025 | STONE HEISZ LESLIED | ▼ Sale | 2,615 | $83.41 | $218K | -7.8% | — |
| Dec 11, 2025 | Chopra DaveenCVP, TMTT & Surgical · O | ▼ Sale | 2,000 | $84.38 | $169K | -5.8% | — |
| Dec 10, 2025 | BOBO DONALD E JRCVP,Strategy/Corp Development · O | ▼ Sale | 11,340 | $83.83 | $951K | -18.4% | plan |
| Dec 10, 2025 | Zovighian Bernard JCEO · O·D | ▼ Sale | 3,863 | $83.45 | $322K | -31% | plan · indirect |
| Dec 9, 2025 | Ullem Scott B.CVP, Chief Financial Officer · O | ▼ Sale | 7,700 | $84.47 | $650K | -16.2% | plan |
| Dec 8, 2025 | Zovighian Bernard JCEO · O·D | ▼ Sale | 21,487 | $85.21 | $1.8M | -20.2% | plan |
| Dec 8, 2025 | Markowitz WayneCVP, JAPAC · O | ▼ Sale | 583 | $86.01 | $50K | -3.2% | — |
| Nov 10, 2025 | Ullem Scott B.CVP, Chief Financial Officer · O | ▼ Sale | 13,000 | $83.08 | $1.1M | -24.6% | plan · 2 tranches |
| Nov 10, 2025 | Lippis Daniel J.CVP, JAPAC · O | ▼ Sale | 1,020 | $82.55 | $84K | -4.4% | plan |
| Aug 25, 2025 | Chopra DaveenCVP, TMTT · O | ▼ Sale | 2,500 | $81.95 | $205K | -7.5% | — |
| Aug 18, 2025 | Wood Larry LGlobal President TAVR & Surg · O | ▼ Sale | 8,950 | $78.06 | $699K | -4.1% | plan |
Every $EW filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Edwards Lifesciences filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $EW feed.